Ardelyx (ARDX) Cash from Investing Activities (2013 - 2026)
Ardelyx's (ARDX) quarterly Cash from Investing Activities came in at -$10.0 million in Q1 2026, down 450.58% YoY from $2.9 million in Q1 2025, and down 364.7% on a QoQ basis from $3.8 million in Q4 2025.
Ardelyx (ARDX) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of Cash from Investing Activities data on file, last reported at -$10.0 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 450.58% year-over-year to -$10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.8 million (down 69.1% YoY) and the FY2025 annual result came in at -$9.0 million, up 51.09% from the prior year.
- Cash from Investing Activities slipped to -$10.0 million in Q1 2026, from $3.8 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $34.9 million in Q2 2025 to a low of -$59.2 million in Q2 2023.
- A 5-year average of -$8.8 million and a median of -$832000.0 in 2022 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities tumbled 3829.93% — and 2025, when it jumped 210.85%.
- Tracing ARDX's Cash from Investing Activities over 5 years: stood at $1.4 million in 2022, then slumped by 2151.84% to -$29.6 million in 2023, then sank by 40.77% to -$41.6 million in 2024, then surged by 109.07% to $3.8 million in 2025, then slumped by 364.7% to -$10.0 million in 2026.
- The last three Cash from Investing Activities figures came in at -$10.0 million (Q1 2026), $3.8 million (Q4 2025), and -$50.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -1.66 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -49.35 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 19.77 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -229.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -363.46 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | 22.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.66 Mn |
| Jun 30, 2026 | 22.66 Mn |
| Mar 31, 2026 | -10.00 Mn |
| Mar 31, 2026 | -10.00 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Dec 31, 2025 | 3.78 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Sep 30, 2025 | -50.51 Mn |
| Jun 30, 2025 | 34.92 Mn |
| Jun 30, 2025 | 34.92 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | -41.62 Mn |
| Dec 31, 2024 | -41.62 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Sep 30, 2024 | 2.34 Mn |
| Jun 30, 2024 | 23.53 Mn |
| Jun 30, 2024 | 23.53 Mn |
| Mar 31, 2024 | -2.57 Mn |
| Mar 31, 2024 | -2.57 Mn |